Estrogen replacement in the menopause

Obstet Gynecol Annu. 1979:8:369-91.

Abstract

PIP: Estrogen replacement in menopause should be used for specific symptoms such as ovarian failure, hot flushes, vaginal atrophy, atrophy of the vulva, and atrophic urethritis. The dose should be as low as possible to be effective and perscribed for as short as time as possible, since there are possible risks of uterine cancer, breast cancer, increased blood pressure, gallstones, deep vein thrombosis, and thromboembolism. Estrogens should be administered to provide the maximum benefit with the minimum risk involved. Estrogens should not be given to patients with known contraindications such as: suspected breast or uterine cancer; undiagnosed genital bleeding; Dubin-Johnson syndrome; acute hepatic disease; previous or present thromboembolism; or severe thrombophlebitis. Careful evaluation should be made before administering estrogen to women with uterine myomata, hyperlipidemia, hypercholesterolemia, sevare varicose veins, chronic hepatic dysfunction, diabetes mellitus, porphyria, or severe hypertension.

Publication types

  • Review

MeSH terms

  • Breast Neoplasms / chemically induced
  • Climacteric
  • Coronary Disease / prevention & control
  • Estradiol Congeners / adverse effects
  • Estradiol Congeners / therapeutic use*
  • Estrogens / deficiency
  • Female
  • Genitalia, Female / physiopathology
  • Humans
  • Menopause*
  • Osteoporosis / prevention & control
  • Ovary / physiopathology
  • Physician-Patient Relations
  • Thromboembolism / chemically induced
  • Uterine Neoplasms / chemically induced

Substances

  • Estradiol Congeners
  • Estrogens